Overview

Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old

Status:
NOT_YET_RECRUITING

Trial end date:
2029-10-04

Target enrollment:

Participant gender:

Summary

The main objective for this study is to evaluate the pharmacokinetics (PK) of crinecerfont in pediatric participants 0 to \<2 years of age with congenital adrenal hyperplasia (CAH).

Phase:

PHASE2

Details

Lead Sponsor:

Neurocrine Biosciences

Treatments:

crinecerfont